| abstract |
GDNF alpha 3 receptor polypeptides and polynucleotides and methods for producingnsuch polypeptides by recombinant techniques are disclosed. Also disclosed are methods fornutilizing GDNF alpha 3 receptor polypeptides and polynucleotides in the design of protocols fornthe treatment of neurodegenerative diseases (such as Parkinson's Disease, amyotrophic lateralnsclerosis (ALS), spinal muscular atrophy (SMA), Huntington's Disease, Alzheimer's Disease,ndiabetic neuropathy), muscular diseases (including the muscular dystrophies) and nerve and musclentrauma, among others and diagnostic assays for such conditions. |